Bristol Myers’ Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction
Bristol Myers Squibb (BMY) reported Q3 revenue of $13.1B, up 7%, with its Growth Portfolio contributing $7.7B, up 12%. EPS was $1.05 GAAP and $1.35 adjusted, down 17%. The company raised 2026 revenue guidance to $49.75B-$50.25B. Growth was driven by multiple drugs, not just one. The earnings decline is due to acquisition-related costs, not weaker core business.
How this was made
The 30-second read
Why it matters
The mixed earnings—revenue growth offset by lower adjusted EPS—creates a nuanced market reaction, with investors weighing guidance against margin compression.
Market read
The new guidance and growth numbers are material for BMY traders and may influence broader pharma sentiment.
What to watch
Potential future erosion of Eliquis patents and the cost of licensed programs may impact long‑term profitability.
Background
Bristol Myers Squibb (BMY) released its third‑quarter results, highlighting a rapidly expanding Growth Portfolio and updated full‑year revenue guidance.
Ticker impact
Bristol Myers reported Q3 Growth Portfolio revenue of $7.7 bn (up 12%) and raised 2026 revenue guidance to $49.75‑$50.25 bn.
modest pressure as the market prices in lower adjusted EPS despite revenue growth
Flat share price and a 17% drop in adjusted EPS suggest short‑term downside, but the raised guidance and strong growth portfolio could limit the decline.
Market effects
Strong growth in oncology and cell therapy may boost biotech sector sentiment.
U.S. pharma stocks could see modest uplift from the guidance raise.
Limited to investors tracking large‑cap pharma earnings.
Counterpoint
The earnings decline and higher licensing costs could signal margin pressure, outweighing revenue growth.
Key entities
- companyBristol Myers Squibb
US‑listed pharmaceutical company reporting Q3 results.
